Literature DB >> 31496584

Evaluation of Computed Tomography Scan and CA 125 Response in Predicting Operability in Advanced Ovarian Cancer and Assessing Survival Outcome in Interval Cytoreductive Surgery.

P Rema1, Elizabeth Reshmi John2,3, Suchetha Samabasivan1, Anil Prahladan4, Preethi George5, J Siva Ranjith1, Shaji Thomas1.   

Abstract

The study aims at the prediction of optimal cytoreduction (OCR) in patients undergoing interval cytoreduction (ICR) in advanced epithelial ovarian cancer (AEOC) based on CT imaging and CA 125 values and assessing the survival pattern of these patients after ICR. This is a prospective observational study of patients with stage III C ovarian cancer who underwent ICR in our institution after neoadjuvant chemotherapy (NACT). All consecutive patients operated from April 2016 to October 2017 were included in the study. From their medical records, their demographic details and clinical variables were recorded. The CA 125 value and CT scan findings before and after chemotherapy were documented. A Bristow's predictive score (BS) was calculated based on the radiological parameters. After ICR, the outcome of the surgery was documented. Optimal cytoreduction (OCR) was defined as no gross residual disease after surgery. The surgical outcome was correlated with the CA 125 difference pre and post chemotherapy and Bristow's predictive score pre and post chemotherapy. The patients were followed up and their survival at 6 and 12 months was assessed. Univariate and multivariate analysis was done to identify factors predicting OCR. 51 patients were included in the study. Age group of the women ranged from 31 to 74 years with a mean of 52 years. Majority of the patients (70.6%) were postmenopausal. Of the 51 women, OCR could be achieved in 31 patients (60.8%). Post-chemotherapy, 36 patients had elevated CA125 above baseline of which 50% attained OCR. Forty six patients had CA 125 response post chemotherapy of which 67.4% attained OCR. Forty five patients had reduction in Bristow Score compared to the pre chemo values of which 64.4% attained OCR which was not found to be statistically significant. Overall survival was 100% survival at 6 months and 92.8% at 12 months in those who achieved OCR. Those with residual disease 0.1-1 cm had survival of 74.1% at 6 and 12 months. Those with residual disease > 1 cm had a survival of 50% at 6 and 12 months. CA125 response has a significant role in predicting OCR while CT evaluation using the BS was not useful in predicting OCR during ICR for AEOC.

Entities:  

Keywords:  CA 125antigen, CT scan; Cytoreduction surgical procedure; Ovarian cancer; Survival analysis

Year:  2019        PMID: 31496584      PMCID: PMC6708039          DOI: 10.1007/s13193-018-0868-x

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  17 in total

1.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

Authors:  Sean Kehoe; Jane Hook; Matthew Nankivell; Gordon C Jayson; Henry Kitchener; Tito Lopes; David Luesley; Timothy Perren; Selina Bannoo; Monica Mascarenhas; Stephen Dobbs; Sharadah Essapen; Jeremy Twigg; Jonathan Herod; Glenn McCluggage; Mahesh Parmar; Ann-Marie Swart
Journal:  Lancet       Date:  2015-05-19       Impact factor: 79.321

Review 2.  2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.

Authors:  Gavin C E Stuart; Henry Kitchener; Monica Bacon; Andreas duBois; Michael Friedlander; Jonathan Ledermann; Christian Marth; Tate Thigpen; Edward Trimble
Journal:  Int J Gynecol Cancer       Date:  2011-05       Impact factor: 3.437

3.  Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer.

Authors:  Aliya Qayyum; Fergus V Coakley; Antonio C Westphalen; Hedvig Hricak; William T Okuno; Bethan Powell
Journal:  Gynecol Oncol       Date:  2005-02       Impact factor: 5.482

4.  Peritoneal metastases: detection with spiral CT in patients with ovarian cancer.

Authors:  Fergus V Coakley; Patricia H Choi; Christina A Gougoutas; Bhavana Pothuri; Ennapadam Venkatraman; Dennis Chi; Antonina Bergman; Hedvig Hricak
Journal:  Radiology       Date:  2002-05       Impact factor: 11.105

5.  The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.

Authors:  D S Chi; E S Venkatraman; V Masson; W J Hoskins
Journal:  Gynecol Oncol       Date:  2000-05       Impact factor: 5.482

6.  Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.

Authors:  Suk-Joon Chang; Robert E Bristow; Hee-Sug Ryu
Journal:  Ann Surg Oncol       Date:  2012-07-06       Impact factor: 5.344

7.  Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.

Authors:  Robert E Bristow; Rafael S Tomacruz; Deborah K Armstrong; Edward L Trimble; F J Montz
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

8.  Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma.

Authors:  B E Nelson; A T Rosenfield; P E Schwartz
Journal:  J Clin Oncol       Date:  1993-01       Impact factor: 44.544

9.  Ovarian carcinoma: value of CT in predicting success of debulking surgery.

Authors:  J I Meyer; A W Kennedy; R Friedman; A Ayoub; R C Zepp
Journal:  AJR Am J Roentgenol       Date:  1995-10       Impact factor: 3.959

10.  Ovarian cancer: staging with CT and MR imaging.

Authors:  R Forstner; H Hricak; K A Occhipinti; C B Powell; S D Frankel; J L Stern
Journal:  Radiology       Date:  1995-12       Impact factor: 11.105

View more
  1 in total

Review 1.  Epithelial ovarian cancer: a review of preoperative imaging features indicating suboptimal surgery.

Authors:  Soo Young Jeong; Tae Joong Kim; Byung Kwan Park
Journal:  J Gynecol Oncol       Date:  2020-04-13       Impact factor: 4.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.